Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers

被引:2
|
作者
Karim, Frederic [1 ]
Amin, Adina [1 ]
Liu, Marie [1 ]
Vishnuvardhan, Nivetha [2 ]
Amin, Saif [1 ]
Shabbir, Raffey [1 ]
Swed, Brandon [3 ]
Khan, Uqba [3 ]
机构
[1] New York Presbyterian Brooklyn Methodist Hosp, Internal Med, 506 6th St, Brooklyn, NY 11215 USA
[2] New York Presbyterian Brooklyn Methodist Hosp, Pediat Hematol Oncol, 506 6th St, Brooklyn, NY 11215 USA
[3] Weill Cornell Med, Hematol Oncol, 515 6th St, Brooklyn, NY 11215 USA
关键词
checkpoint inhibitors; esophageal cancer; gastric cancer; immunotherapy; PD-L1; HER2; clinical trials; HELICOBACTER-PYLORI INFECTION; ESOPHAGEAL CANCER; PLUS CHEMOTHERAPY; GASTRIC-CANCER; BARRETTS-ESOPHAGUS; 1ST-LINE TREATMENT; DOUBLE-BLIND; NIVOLUMAB; JUNCTION; HER2;
D O I
10.3390/cancers15164099
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This article reviews the essential clinical trials that have led to these immunother-apy approvals and explores the use of predictive biomarkers, such as PD-L1 expression and MSI status, to identify patients who are most likely to benefit from immunotherapies. Methods: This case review series describe findings from different clinical trials and contribute to the evolving understanding of the role of CPIs in managing advanced gastroesophageal cancers and may lead to improved treatment options and patient outcomes. Ongoing clinical trials also hold promise for expanding treatment options and improving patient outcomes in the future. Methods: The systematic review followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The protocol has not been registered. A systematic literature review was conducted to identify relevant clinical trials and studies that describe the role of immune checkpoint inhibitors in managing advanced gastroesophageal cancers. Electronic database (PubMed, Clinicaltri-als.gov, Society of Immunotherapy of Cancer, Aliment Pharmacology & Therapeutics, BMC cancer, Molecular Cancer Research, Nature Reviews Molecular Cell Biology, American Association for Cancer Research, Science, Nature, Cancer Discovery, Journal of the National Cancer Institute, Advanced Immunology, Oncotarget, Nature Medicine, Nature Genetics, Gut, Pathology and Oncology Research, Journal of Clinical Oncology, The New England Journal of Medicine, Gastrointestinal oncology, JAMA Oncology, Journal of Gastrointestinal Oncology, Current Oncology, Annals of Oncology, The Lancet, JCO Oncology Practice, Future Oncology, Gastric Cancer, CA: A Cancer Journal for Clinicians, American Journal of Gastroenterology, Gastroenterology, Journal of the National Cancer Institute, International Journal of Epidemiology, Helicobacter, Gastroenterology Review) were searched using a combination of relevant keywords and MESH terms. The search encompassed articles published up to 5/2023. Additionally, manual searches of reference lists of selected articles and pertinent review papers were conducted to ensure comprehensive coverage of relevant studies. Studies were included if they provided insights into clinical trials evaluating the efficacy and safety of CPIs in
引用
收藏
页数:18
相关论文
共 50 条
  • [1] The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer
    Murphy, Adrian G.
    Kelly, Ronan J.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (03) : 485 - +
  • [2] Immune checkpoint inhibitors in resectable gastroesophageal cancers-a review
    Mukherjee, Sarbajit
    Parmar, Kanak
    Smyth, Elizabeth
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [3] Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy
    Smyth, E. C.
    Gambardella, V
    Cervantes, A.
    Fleitas, T.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (05) : 590 - 599
  • [4] Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors
    Ma, Shuang
    Chen, Fei
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2022, 238
  • [5] Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers
    Mascaretti, Federica
    Haider, Salman
    Amoroso, Chiara
    Caprioli, Flavio
    Ramai, Daryl
    Ghidini, Michele
    [J]. JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (02) : 662 - 678
  • [6] The emerging role of checkpoint inhibitors for rare genitourinary cancers
    Jeanny B. Aragon-Ching
    [J]. Nature Reviews Urology, 2021, 18 : 133 - 134
  • [7] The emerging role of checkpoint inhibitors for rare genitourinary cancers
    Aragon-Ching, Jeanny B.
    [J]. NATURE REVIEWS UROLOGY, 2021, 18 (03) : 133 - 134
  • [8] Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
    Sundar, Raghav
    Smyth, Elizabeth C.
    Peng, Siyu
    Yeong, Joe P. S.
    Tan, Patrick
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [9] Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer
    Chenard-Poirier, Maxime
    Smyth, Elizabeth C.
    [J]. DRUGS, 2019, 79 (01) : 1 - 10
  • [10] Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer
    Maxime Chénard-Poirier
    Elizabeth C. Smyth
    [J]. Drugs, 2019, 79 : 1 - 10